Corporate Overview
Cytonics is a clinical-stage biotechnology company developing CYT-108, a genetically engineered Alpha-2-Macroglobulin (A2M) protein variant, designed to treat osteoarthritis (OA) at its molecular origins. Built on over 15 years of foundational science, Cytonics has pioneered the therapeutic use of A2M, a naturally occurring protease inhibitor, and engineered it into a recombinant platform with potent disease-modifying potential. Unlike traditional therapies that only manage symptoms, CYT-108 targets the enzymes that actively destroy cartilage, offering the potential to slow or halt disease progression for the first time and giving over 500M suffering patients their lives back.
Cytonics combines scientific credibility with capital efficiency to offer a uniquely de- risked biotech opportunity. Our first-generation treatment, the Autologous Protease Inhibitor Concentrate (APIC) therapy, has treated over 10,000 osteoarthritis patients, providing real-world validation for A2M as a viable OA therapy, and de-risking the development of our CYT-108 variant. Unlike traditional biotechs dependent on Venture Capital financing and Big Pharma partnerships, we’ve raised over $15 million from 6,000+ individual investors via equity crowdfunding, maintaining strategic independence and a clean, founder-aligned cap table.
CYT-108 is currently advancing through a first-in-human Phase 1 clinical trial in osteoarthritis patients.
15+ Years of
Research
Recombinant A2M Platform
10,000+ Patients Treated with APIC
6,000+ Grassroots Investors
$15M+ Raised via
Crowdfunding
Phase 1 Trial in
Progress
Targeting $500B Global
OA Market
Press Releases
Milestones
2006-2013Foundation and Early Innovation
Founded in 2006 as Gamma Spine, the company pioneered their first generation “APIC “therapy for osteoarthritis. The company was then rebranded as Cytonics Corporation in 2007. By 2013, APIC secured FDA 510(k) clearance as a PRP-based medical device.
2014-2015Early Commercial and Scientific Progress
APIC was out-licensed internationally, and the team began engineering CYT-108, a recombinant A2M molecule, demonstrating its superior efficacy over natural A2M in preclinical studies.
2016-2017Overcoming Scientific Challenges
Developed GMP-grade CYT-108, a complex and massive protein structure – a major breakthrough in drug development.
2018Strategic Leadership Shift
Joey Bose was appointed CEO to recapitalize and fast-track CYT-108’s development.
2019-2020Preclinical Validation and Market Expansion
Completed preclinical trials clearly demonstrating CYT-108’s safety and superior efficacy over the natural A2M leveraged by the APIC therapy. APIC was licensed for veterinary use and Cytonics launched its first equity crowdfunding campaign ($545K).
2021-2022Capital Raised and Clinical Readiness
Raised $9M through Regulation A+ on SeedInvest and completed IND enabling studies, paving the way for human trials.
2023-2024Human Trials and Major MilestonesSecured additional $6M via DealMaker and StartEngine equity crowdfunding platforms. In June 2024, CYT-108 was dosed in first-in human Phase 1 study – a pivotal clinical development milestone.2025Ongoing Clinical Success and Expansion
By May 2025, all patients had completed the Phase 1 trial. As of June 2024, a new Regulation A+ raise ($20M) is currently underway to support further development.
Upcoming Milestones
Cytonics anticipates submitting an IND application to the FDA in 4Q25. The clinical operations team has expanded in anticipation of Phase 1b/2a trials in early 2026. The ongoing Reg A+ raise is expected to conclude in March 2026.
@media (max-width: 1024px){ .twae-wrapper{–tw-ybx-size: 80px !important;}}@media (max-width: 767px){ .twae-wrapper{–tw-ybx-size: 80px !important}}
Investor Presentation
Investor Presentation – From scalpel to startup: a surgeon’s discovery. A biotech
rebellion.
This investor deck lays out how we’re developing the first disease-modifying therapy for osteoarthritis, how we’ve raised over $15M from 6,000+ grassroots investors, and why our recombinant A2M platform could unlock a $500B market opportunity. Inside you’ll find:
- The science behind A2M
- CYT-108 clinical data and preclinical results
- IP strategy and global patent coverage
- Capital strategy and exit scenarios
- Our plan to succeed where Big Pharma has failed
Intellectual Property
A Globally Protected Platform Built to Last
Cytonics has built a robust and multi-layered intellectual property portfolio around its therapeutic platform targeting osteoarthritis and degenerative joint diseases. Our IP strategy protects not only CYT-108, our lead recombinant A2M biologic, but also the underlying protein engineering methods, manufacturing processes, and broad therapeutic applications of our technology.
A Multi-Layered Approach to IP Protection
Cytonics holds 25 issued patents and multiple pending applications across the United States, European Union, Canada, Australia, Japan, United Kingdom, Germany, and France. These patents encompass:
- Composition of matter for recombinant A2M variants, including CYT-108
- Formulation and delivery technologies for intra-articular and systemic administration
- Manufacturing and purification processes for scalable biologic production
Our IP estate provides protection through at least 2040, with ongoing filings that reflect insights gained from our preclinical studies and Phase 1 clinical trial.
Protecting a Platform, Not Just a Product
Cytonics’ IP extends beyond osteoarthritis, with patent claims supporting expansion into other protease-driven and inflammatory conditions — including rheumatoid arthritis, post-traumatic joint degeneration, and potentially neuroinflammatory disorders.
This broad coverage positions Cytonics as a platform company with the freedom to operate across multiple indications and delivery modalities, while maintaining long-term exclusivity.
For prospective partners or investors, a full list of granted patents and pending applications is available upon request.
Contact Us to request IP materials or access our data room.
Blogs
#55 🧬 Perfecting Nature’s Blueprint
#54 🌿 The Beauty of Nature’s Design
#53 🧪 The Experiment That Started It All
#55 🧬 Perfecting Nature’s Blueprint
#54 🌿 The Beauty of Nature’s Design
